antiviral news

Press Releases in the global landscape

Mar 4, 2026

Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M

Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients.

Mar 2, 2026

Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M

Bioxytran reported positive Phase 1b/2a trial results for its antiviral candidate ProLectin-M in mild to moderate COVID-19, showing faster viral clearance and a favorable safety profile.

Feb 27, 2026

KDCA to halt use of unapproved Covid-19 drug Lagevrio as stock runs out

The Korea Disease Control and Prevention Agency announced it will suspend use of the COVID-19 drug Lagevrio (molnupiravir) due to depleted stock and incomplete product approval.

Feb 19, 2026

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID®-ineligible patients, representing a significant population with no effective treatment options.

Feb 5, 2026

The Ministry of Health has approved nine home treatment regimens for COVID-19

Feb 1, 2026

The Ministry of Health approved permanent recommendations for the treatment of COVID-19

Among the drugs recommended for use in outpatient settings are molnupiravir, favipiravir, nirmatrelvir with ritonavir, as well as other active substances.